Publication Date
7-15-2024
Document Type
Article
Organizational Units
Daniels College of Business, Management
Keywords
Alzheimer’s disease, Research and development consortia, Pharmaceutical industry, Drug development, Public-private partnerships, Ecosystem
Abstract
Efforts to accelerate Alzheimer's disease (AD) drug development have been spurred on by the creation of open science, public-private R&D consortia. An R&D consortium provides an improved structure for generating and disseminating AD knowledge across a range of organizations while also aligning their interests. Drawing from archival and interview data collected on 46 public-private R&D consortia focused wholly or in part on AD, we uncover two important innovations: the creation of novel consortium types that facilitate coordination beyond the individual consortium, and the practice of organizations joining multiple consortia. Collectively these innovations provide member organizations with different pathways for advancing AD research. These findings have significant implications for how member organizations should approach collaboration in the AD drug development process.
Copyright Date
7-25-2024
Copyright Statement / License for Reuse
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Rights Holder
West, Joel and Olk, Paul
Provenance
Received from Elsevier
File Format
application/pdf
Language
English (eng)
Extent
6 pgs
File Size
321 KB
Publication Statement
Copyright is held by the Authors. User is responsible for all copyright compliance. This article was originally published as
West, J. & Olk, P. (2024). Developing Public-Private R&D Consortia to Accelerate Alzheimer's Disease Drug Development. Drug Discovery Today, 29, 9. https://doi.org/10.1016/j.drudis.2024.104103
Publication Title
Drug Discovery Today
Volume
29
Issue
9
First Page
104103
ISSN
1359-6446
PubMed ID
39019427
Recommended Citation
West, Joel and Olk, Paul, "Developing Public-Private R&D Consortia to Accelerate Alzheimer’s Disease Drug Development" (2024). Management: Faculty Scholarship. 2.
https://digitalcommons.du.edu/management_fac/2
https://doi.org/10.1016/j.drudis.2024.104103
Included in
Business Administration, Management, and Operations Commons, Health Policy Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons